NZ grower brings new medicinal cannabis to market: "Different ratios of cannabinoids"

Cannasouth Limited announced that three cannabinoid products were successfully assessed by the Medicinal Cannabis Agency (Agency).

Successful assessment by the Medicinal Cannabis Agency of Cannasouth's first medicinal cannabis products will deliver wider treatment options to New Zealand patients and prescribers.

Cannasouth CEO Mark Lucas says their products differ from other medicinal cannabis products on the New Zealand market because they contain different ratios of cannabinoids.

"The differentiated formulations of our products will provide New Zealand patients and prescribers with new treatment options compared to existing products on the New Zealand market. At the moment, the products available offer very few differences in formulation. We are confident these products offer patients and prescribers a point of difference to meet the treatment needs of a wider range of conditions."

"Full-spectrum extracts contain complex mixtures of cannabinoids. While the technical challenges from this did result in us navigating a lengthy regulatory pathway, the wait is worthwhile because of the benefits patients will receive from these enhanced product options."

Agency approval of these products is a major step forward for Cannasouth in terms of generating medicinal cannabis revenue. Revenue generation from the sale of medicines in New Zealand, in addition to high-quality dried flower biomass, is one of the company's key goals for 2022.

This will complement Cannasouth's existing non-cannabinoid revenues generated through its subsidiary Midwest Pharmaceutics NZ Ltd, which sells products and services to the pharmaceutical, health, and wellness supplement sectors.

Cannasouth is also close to harvesting its first commercial crop of medicinal cannabis flower at its controlled environment agriculture (CEA) cultivation facility in the Waikato while progressing GACP and GMP certification.